Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Acasunlimab |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | sensitive | Acasunlimab | Preclinical | Actionable | In a preclinical study, Acasunlimab (GEN1046) treatment resulted in T-cell activation and proliferation and induced T-cell-mediated cytotoxicity of CD274 (PD-L1)-positive tumor cells in culture, and induced tumor regression in a transgenic mouse model expressing human CD274 (PD-L1) (PMID: 35176764). | 35176764 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35176764) | Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. | Full reference... |